Stifel reiterates Buy rating on Boston Scientific stock with $125 target
PositiveFinancial Markets

Stifel has reaffirmed its Buy rating on Boston Scientific stock, setting a target price of $125. This endorsement reflects confidence in the company's growth potential and market position, which is significant for investors looking for promising opportunities in the healthcare sector.
— Curated by the World Pulse Now AI Editorial System